[{"address1": "6 Liberty Square", "address2": "Suite 2382", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "857 837 3099", "website": "https://www.transcodetherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas A. Fitzgerald M.B.A.", "age": 71, "title": "Interim CEO, CFO, President, VP of Administration & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 358138, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.", "age": 64, "title": "Executive Chairman of the Board", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 102500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zdravka  Medarova Ph.D.", "age": 48, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anna  Moore Ph.D.", "age": 61, "title": "Co-Founder, Scientific Advisor & Member of Scientific Advisory Board", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Duggan M.B.A., R.N.", "title": "Senior Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel R. Vlock M.D.", "age": 71, "title": "Chief Medical Officer", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.707, "open": 0.75, "dayLow": 0.695, "dayHigh": 1.05, "regularMarketPreviousClose": 0.707, "regularMarketOpen": 0.75, "regularMarketDayLow": 0.695, "regularMarketDayHigh": 1.05, "beta": -0.34, "forwardPE": -1.2238805, "volume": 5922050, "regularMarketVolume": 5922050, "averageVolume": 442982, "averageVolume10days": 655050, "averageDailyVolume10Day": 655050, "bid": 0.7946, "ask": 0.8456, "bidSize": 100, "askSize": 100, "marketCap": 4762601, "fiftyTwoWeekLow": 0.42, "fiftyTwoWeekHigh": 309.6, "fiftyDayAverage": 0.63786, "twoHundredDayAverage": 20.268684, "currency": "USD", "enterpriseValue": 2445576, "floatShares": 5805904, "sharesOutstanding": 5808050, "sharesShort": 18555, "sharesShortPriorMonth": 174746, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0032, "heldPercentInsiders": 0.00139, "heldPercentInstitutions": 0.00274, "shortRatio": 0.06, "shortPercentOfFloat": 0.0032, "bookValue": 2.615, "priceToBook": 0.31357554, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -18546096, "trailingEps": -4144.4, "forwardEps": -0.67, "enterpriseToEbitda": -0.127, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RNAZ", "underlyingSymbol": "RNAZ", "shortName": "TransCode Therapeutics, Inc.", "longName": "TransCode Therapeutics, Inc.", "firstTradeDateEpochUtc": 1625751000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "09a0c637-96b3-3583-b5c0-c18005c44a45", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.82, "targetHighPrice": 120.0, "targetLowPrice": 120.0, "targetMeanPrice": 120.0, "targetMedianPrice": 120.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 2767598, "totalCashPerShare": 0.477, "ebitda": -19295032, "totalDebt": 450571, "quickRatio": 0.793, "currentRatio": 1.276, "debtToEquity": 27.46, "returnOnAssets": -1.90263, "returnOnEquity": -7.5985103, "freeCashflow": -11208726, "operatingCashflow": -18074536, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]